

FOI 2992

3rd April 2025

FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

Q1. How many early-stage (non-metastatic or Stages 1-3) non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:

- **Atezolizumab (Tecentriq)**
- **Durvalumab (Imfinzi)**
- **Nivolumab (Opdivo)**
- **Pembrolizumab (Keytruda)**
- **Chemotherapy**
- **Radiotherapy**
- **Chemotherapy AND Radiotherapy**
- **Osimertinib**

Response:

Not available for pharmacy data.

In order, to provide this information a significant trawl of records from a number of sources is required. The cost of locating and retrieving the information exceeds the “appropriate limit” as stated in the Freedom of Information (Fees and Appropriate Limit) Regulations 2004. In order to obtain this information, it would exceed the £450 limit and is therefore cost prohibitive.

Under section 12 of the Freedom of Information Act 2000, Public Authorities are not obliged to comply with an information request where to do so would exceed the cost limit.

In addition, it would not be appropriate to search through individual patient records for the purposes for responding to a FOI request, there would be no patient expectation that medical records would be used in this way.

If you are able to refine your request, so that it is more likely to fall under the cost limit, we will consider it again. Please contact us for advice and assistance on refining your request if required.

Q2. How many patients has your trust treated in the last 3 months with Pembrolizumab for stage II Melanoma?

Response:

None

Email: foi.team@southerntrust.hscni.net